Robert F. Kennedy Jr.’s Billion-Dollar Hit to Big Pharma

The decline in share prices for vaccine manufacturers is likely to continue as uncertainty grows over Kennedy's potential policies and their implications for the vaccine market. Investors may want to be cautious about holding positions in companies heavily reliant on vaccine sales until the regulatory landscape becomes clearer.

Similarly, Moderna could face headwinds as investor sentiment may remain cautious with increased scrutiny on vaccine mandates and overall public health strategies amidst Kennedy’s leadership. The company's reliance on mRNA technology and the current climate may lead to further declines in share prices.